The FDA has proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list — the register of active pharmaceutical ingredients that large-scale compounding operations may use to compound medicines in bulk.
The agency’s stated rationale is that after reviewing nominations, it did not identify a clinical need for factory-scale compounding of these three GLP-1 molecules when FDA-approved products are commercially available. The proposal was announced April 30, 2026, and published in the Federal Register on May 1, 2026.
The comment period was extended to July 30, 2026. As of October 9, 2026, no final determination has been published, and the rule remains a proposal — not a final FDA decision.
What happened
The FDA’s proposed rule would remove semaglutide, tirzepatide, and liraglutide from the list of bulk drug substances that 503B outsourcing facilities are permitted to use. 503B facilities are large-scale compounding operations that can manufacture medications without patient-specific prescriptions, subject to FDA oversight.
According to the agency, it reviewed nominations for these substances and did not identify a demonstrated clinical need for bulk compounding of these GLP-1 drugs when FDA-approved versions are on the market. The proposal was published in the Federal Register on May 1, 2026, with the public comment period later extended through July 30, 2026.
As of October 9, 2026, the FDA had not issued a final rule. The proposal remains under review.
Why it matters
If finalized, the rule would permanently close the 503B pathway for semaglutide, tirzepatide, and liraglutide — even if a future drug shortage occurs. This would close the last regulatory door that could reopen mass compounding of these drugs after a market disruption.
The proposal also creates a potential conflict with the pending HHS enforcement discretion plan, which could allow the same peptides through a different mechanism. If both policies move forward, the regulatory landscape for GLP-1 compounding could be left in fundamental contradiction.
Several groups are affected by the outcome, including:
- 503B outsourcing facilities
- 503A compounding pharmacies (patient-specific compounding is unaffected by this proposal)
- Telehealth GLP-1 platforms
- GLP-1 patients
- Pharmacy benefit managers
What to watch next
The key development is whether and when the FDA publishes a final determination. A finalized exclusion would remove 503B bulk compounding access to these three GLP-1 molecules regardless of future shortage status.
Observers are also watching how this proposal interacts with the HHS stopgap plan, which could create a parallel pathway for the same peptides. The relationship between the two policies remains unresolved.
Sources
Industry information only. Not medical or legal advice.
